In April 2017, the U.S. Department of Veterans Affairs (VA) and the U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the management of type 2 diabetes mellitus.

The VA/DoD Evidence-Based Practice Work Group convened a joint VA/DoD guideline development effort that included a multidisciplinary panel of practicing clinician stakeholders and conformed to the Institute of Medicine's tenets for trustworthy clinical practice guidelines. The guideline panel developed key questions in collaboration with the ECRI Institute, which systematically searched and evaluated the literature through June 2016, developed an algorithm, and rated recommendations by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.

This synopsis summarizes key features of the guideline in 7 areas: patient-centered care and shared decision making, glycemic biomarkers, hemoglobin A_1c target ranges, individualized treatment plans, outpatient pharmacologic treatment, glucose targets for critically ill patients, and treatment of hospitalized patients.

2017 年 4 月，美国退伍军人事务部 (VA) 和美国国防部 (DoD) 批准了一项针对 2 型糖尿病管理的联合临床实践指南。

VA/DoD 循证实践工作组召集了一个联合 VA/DoD 指南制定工作，其中包括一个由执业临床医生利益相关者组成的多学科小组，并符合医学研究所关于值得信赖的临床实践指南的原则。指南小组与 ECRI 研究所合作开发了关键问题，该研究所系统地搜索和评估了截至 2016 年 6 月的文献，开发了一种算法，并使用 GRADE（推荐评估、开发和评估分级）系统对推荐进行了评级。

本概要总结了指南在 7 个领域的主要特点：以患者为中心的护理和共同决策、血糖生物标志物、血红蛋白 A _1c目标范围、个体化治疗计划、门诊药物治疗、危重患者的血糖目标和住院患者的治疗.